Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

161. Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New York (PubMed)

Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New York Trans-fatty acids (TFAs) have deleterious cardiovascular effects. Restrictions on their use were initiated in 11 New York State (NYS) counties between 2007 and 2011. The US Food and Drug Administration plans a nationwide restriction in 2018. Public health implications of TFA restrictions are not well understood.To determine whether TFA restrictions in NYS counties were (...) associated with fewer hospital admissions for myocardial infarction (MI) and stroke compared with NYS counties without restrictions.We conducted a retrospective observational pre-post study of residents in counties with TFA restrictions vs counties without restrictions from 2002 to 2013 using NYS Department of Health's Statewide Planning and Research Cooperative System and census population estimates. In this natural experiment, we included those residents who were hospitalized for MI or stroke. The data

Full Text available with Trip Pro

2017 JAMA cardiology

162. The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR (PubMed)

The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR To investigate the obesity paradox and association of extreme obesity with long-term outcomes among older ST-segment elevation myocardial infarction (STEMI) patients.Nineteen thousand four hundred and ninety-nine patients ≥65 years with STEMI surviving to hospital discharge in NCDR ACTION Registry-GWTG linked to Centers for Medicare and Medicaid

Full Text available with Trip Pro

2017 European heart journal. Quality of care & clinical outcomes

163. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. (PubMed)

Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. In patients with ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to restore blood flow in an infarct-related coronary artery improves outcomes. The use of PCI in non-infarct-related coronary arteries remains controversial.We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI of an infarct-related coronary artery (...) in a 1:2 ratio to undergo complete revascularization of non-infarct-related coronary arteries guided by fractional flow reserve (FFR) (295 patients) or to undergo no revascularization of non-infarct-related coronary arteries (590 patients). The FFR procedure was performed in both groups, but in the latter group, both the patients and their cardiologist were unaware of the findings on FFR. The primary end point was a composite of death from any cause, nonfatal myocardial infarction, revascularization

2017 NEJM

164. The neuroprotective agent Rasagiline mesylate attenuates cardiac remodeling after experimental myocardial infarction (PubMed)

The neuroprotective agent Rasagiline mesylate attenuates cardiac remodeling after experimental myocardial infarction Rasagiline mesylate (N-propargyl-1 (R)-aminoindan) (RG) is a selective, potent irreversible inhibitor of monoamine oxidase-B with cardioprotective and anti-apoptotic properties. We investigated whether it could be cardioprotective in a rat model undergoing experimental myocardial infarction (MI) by permanent ligation of the left anterior descending coronary artery.RG (...) content and attenuated the number of apoptotic myocytes in the border zone (65%) as indicated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Caspase 3 relative protein levels were significantly decreased in the non-infarcted myocardium. Markedly decreased malondialdehyde levels in the border zone indicate a reduction in tissue oxidative stress.Our study demonstrates a positive effect of RG in the post-MI period with a significant attenuation in cardiac remodelling.©

Full Text available with Trip Pro

2017 ESC heart failure

165. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. (PubMed)

One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin with routine or optional use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction (STEMI). Few data are available

Full Text available with Trip Pro

2017 JAMA cardiology

166. A System of Care for Patients With ST-Segment Elevation Myocardial Infarction in India: The Tamil Nadu–ST-Segment Elevation Myocardial Infarction Program (PubMed)

A System of Care for Patients With ST-Segment Elevation Myocardial Infarction in India: The Tamil Nadu–ST-Segment Elevation Myocardial Infarction Program Challenges to improving ST-segment elevation myocardial infarction (STEMI) care are formidable in low- to middle-income countries because of several system-level factors.To examine access to reperfusion and percutaneous coronary intervention (PCI) during STEMI using a hub-and-spoke model.This multicenter, prospective, observational study

Full Text available with Trip Pro

2017 JAMA cardiology

167. Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. (PubMed)

Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. Ischemic postconditioning of the heart during primary percutaneous coronary intervention (PCI) induced by repetitive interruptions of blood flow to the ischemic myocardial region immediately after reopening of the infarct-related artery may limit myocardial damage.To determine whether ischemic postconditioning can (...) improve the clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI).In this multicenter, randomized clinical trial, patients with onset of symptoms within 12 hours, STEMI, and thrombolysis in myocardial infarction (TIMI) grade 0-1 flow in the infarct-related artery at arrival were randomized to conventional PCI or postconditioning. Inclusion began on March 21, 2011, through February 2, 2014, and follow-up was completed on February 2, 2016. Analysis was based on intention

Full Text available with Trip Pro

2017 JAMA cardiology

168. Acute myocardial infarction hospital admissions and deaths in England: a national follow-back and follow-forward record-linkage study (PubMed)

Acute myocardial infarction hospital admissions and deaths in England: a national follow-back and follow-forward record-linkage study Little information is available on how primary and comorbid acute myocardial infarction contribute to the mortality burden of acute myocardial infarction, the share of these deaths that occur during or after a hospital admission, and the reasons for hospital admission of those who died from acute myocardial infarction. Our aim was to fill in these gaps (...) in the knowledge about deaths and hospital admissions due to acute myocardial infarction.We used individually linked national hospital admission and mortality data for England from 2006 to 2010 to identify all primary and comorbid diagnoses of acute myocardial infarction during hospital stay and their associated fatality rates (during or within 28 days of being in hospital). Data were obtained from the UK Small Area Health Statistics Unit and supplied by the Health and Social Care Information Centre (now NHS

Full Text available with Trip Pro

2017 The Lancet. Public health

169. Types of myocardial infarction among HIV-infected individuals in the United States (PubMed)

Types of myocardial infarction among HIV-infected individuals in the United States The Second Universal Definition of Myocardial Infarction (MI) divides MIs into different types. Type 1 MIs result spontaneously from instability of atherosclerotic plaque, whereas type 2 MIs occur in the setting of a mismatch between oxygen demand and supply, as with severe hypotension. Type 2 MIs are uncommon in the general population, but their frequency in human immunodeficiency virus (HIV)-infected

Full Text available with Trip Pro

2017 JAMA cardiology

170. [Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec]

[Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec] Portrait de la prise en charge de l'infarctus aigu du myocarde avec élévation du segment ST au Québec en 2013-2014 : résultats d'une troisième évaluation terrain à l'échelle provinciale [Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec] Portrait de la prise en charge de l'infarctus aigu du myocarde avec élévation du (...) segment ST au Québec en 2013-2014 : résultats d'une troisième évaluation terrain à l'échelle provinciale [Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec] Azzi L, Boothroyd L, Bogaty P, Lambert L, Désy F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Azzi L, Boothroyd L, Bogaty P

2017 Health Technology Assessment (HTA) Database.

171. [Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec (Review)]

[Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec (Review)] Normes relatives aux traitements de reperfusion de l'infarctus aigu du myocarde avec élévation du segment ST (IAMEST) au Québec [Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec (Review)] Normes relatives aux traitements de reperfusion de l'infarctus aigu du myocarde avec élévation du segment ST (IAMEST) au (...) Québec [Standards regarding reperfusion treatments for ST-segment elevation acute myocardial infarction (STEMI) in Quebec (Review)] Azzi L, Boothroyd L, Bogaty P, Lambert L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Azzi L, Boothroyd L, Bogaty P, Lambert L. Normes relatives aux traitements de reperfusion de l'infarctus aigu du myocarde

2017 Health Technology Assessment (HTA) Database.

172. Diagnosing acute myocardial infarction in the presence of ventricular pacing: can Sgarbossa criteria help?

Diagnosing acute myocardial infarction in the presence of ventricular pacing: can Sgarbossa criteria help? BestBets: Diagnosing acute myocardial infarction in the presence of ventricular pacing: can Sgarbossa criteria help? Diagnosing acute myocardial infarction in the presence of ventricular pacing: can Sgarbossa criteria help? Report By: Arunan Jothieswaran - Medical Student Search checked by Dr Richard Body - Consultant in Emergency Medicine, Institution: The University of Manchester (...) to the ED with acute chest pain. His ECG shows ventricular paced rhythm with left bundle branch block morphology. You are aware that the Sgarbossa criteria could be used to diagnose acute myocardial infarction (AMI) in this context1 and that the modification to those criteria proposed by Smith et al 2 could improve diagnostic accuracy. You wonder if the same criteria can be applied to diagnose AMI in patients with ventricular paced rhythm. Search Strategy We searched the MEDLINE (1946 to May Week 2

2017 BestBETS

173. Assessing and Refining Myocardial Infarction Risk Estimation among Patients with Human Immunodeficiency Virus: Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) (PubMed)

Assessing and Refining Myocardial Infarction Risk Estimation among Patients with Human Immunodeficiency Virus: Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Persons with human immunodeficiency virus (HIV) that is treated with antiretroviral therapy have improved longevity but face an elevated risk of myocardial infarction (MI) due to common MI risk factors and HIV-specific factors. Despite these elevated MI rates, optimal methods to predict MI risks for HIV-infected (...) with complete baseline data, 6904 were white and 9250 were men. Myocardial infarction rates were higher among black men (6.9 per 1000 person-years) and black women (7.2 per 1000 person-years) than white men (4.4 per 1000 person-years) and white women (3.3 per 1000 person-years), older participants (7.5 vs 2.2 MI per 1000 person-years for adults 40 years and older vs < 40 years old at study entry, respectively), and participants who were not virally suppressed (6.3 vs 4.7 per 1000 person-years

Full Text available with Trip Pro

2017 JAMA cardiology

174. ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

175. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

176. Beta blockers during acute ST-elevation myocardial infarction (STEMI)

Beta blockers during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus